Please assess the completion status of the following clinical trial:

Trial Title: Head-to-head Comparison of Empagliflozin and Dapagliflozin

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Inadequately controlled under triple OADs (metformin, glimepiride, dipeptidyl peptidase inhibitor) as evidenced by HbA1c 7.5-12%~Exclusion Criteria:~* Type 1 diabetes~* Gestational diabetes~* Diabetes due to secondary causes~* Receiving anticancer treatment~* Receiving glucocorticoids or immune-suppressants~* have been treated with sodium-glucose co-transporter 2 inhibitors for more than 7 consecutive days within 3 months before entering this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Triple OADs failure (Type: None): Empagliflozin or dapagliflozin as an add-on drug for inadequately controlled T2D patients who are already receiving a regimen of three distinct OADs, including metformin, glimepiride and dipeptidyl peptidase 4 (DPP4) inhibitors.

Based on this trial design, predict the completion outcome and termination type (if applicable).